Literature DB >> 7605852

Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial.

L Laine1, F Cominelli, R Sloane, V Casini-Raggi, M Marin-Sorensen, W M Weinstein.   

Abstract

BACKGROUND: H. pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) are major causes of gastroduodenal injury in man. We assessed the effect of daily NSAID ingestion on gastric histology and the interaction of H. pylori infection and NSAID ingestion on gross and histological injury and prostaglandin production.
METHODS: Fifty-two healthy volunteers with normal baseline endoscopy were randomly assigned to receive identical-appearing naproxen 500 mg b.d., etodolac 400 mg b.d., or placebo b.d. for 4 weeks. The number and size of all erosions and ulcers were recorded by endoscopy at weeks 1 and 4. Biopsies taken at baseline, week 1 and week 4 were assessed for H. pylori, histology and gastric prostaglandin E2 production.
RESULTS: No significant changes occurred with treatment in any histological feature in the three study groups or in H. pylori positive or negative subsets. Antral inflammation scores (scale, 0-6) for the NSAID group were: week 0--1.2 +/- 0.3; week 1--1.1 +/- 0.3; week 4--1.3 +/- 0.3; findings of 'chemical gastritis' were not seen. No significant difference in gross gastroduodenal injury (number or total surface area of ulcers or erosions) was seen between H. pylori positive and negative subjects in the three groups at week 1 or 4. Baseline prostaglandin E2 production was significantly higher in H. pylori positive subjects (2398 +/- 400 vs. 1064 +/- 255 pg/mg protein) and decreased significantly with 1 week of naproxen in H. pylori positive and negative subjects.
CONCLUSIONS: NSAID ingestion does not cause diffuse histological injury. Any diffuse histological injury in the gastric mucosa is related to the presence of H. pylori, and this H. pylori-associated gastritis is not altered by NSAID ingestion. Furthermore, the development of gross gastroduodenal damage with 4 weeks of NSAID use is not influenced by underlying H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605852     DOI: 10.1111/j.1365-2036.1995.tb00361.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells.

Authors:  Mohamed M M Abdel-Latif; Henry Windle; Ana Terres; Déirdre Ní Eidhin; Dermot Kelleher; John V Reynolds
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

Review 2.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

3.  Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery Disease.

Authors:  Chang Kyu Choi; Nayoung Kim; Jin Woo Choi; Young Soo Park; Jin-Wook Kim; Sook-Hyang Jeong; Dong Ho Lee; Young-Seok Cho; Tae-Jin Youn; Woo-Young Chung; In-Ho Chae; Dong-Ju Choi
Journal:  Gut Liver       Date:  2008-09-30       Impact factor: 4.519

4.  Effect of high-dose aspirin on Helicobacter pylori eradication.

Authors:  Seung Ha Park; Dong Il Park; Sang Hoon Kim; Hong Joo Kim; Yong Kyun Cho; In Kyung Sung; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Keuk Keum
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 5.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Cyclooxygenase inhibition: between the devil and the deep blue sea.

Authors:  C J Hawkey
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

7.  NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite.

Authors:  Akiko Shiotani; Yoshio Yamaoka; Hala M T El-Zimaity; M Ali Saeed; Waqar A Qureshi; David Y Graham
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

8.  Long-term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation.

Authors:  Tetsuya Tanigawa; Toshio Watanabe; Kazuhide Higuchi; Kazunari Tominaga; Yasuhiro Fujiwara; Nobuhide Oshitani; Andrzej S Tarnawski; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

9.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

10.  Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents.

Authors:  W H Wang; W M Wong; D Dailidiene; D E Berg; Q Gu; K C Lai; S K Lam; B C Y Wong
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.